|
Market Closed -
Nasdaq
00:00:00 17/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 167.58 USD | -0.30% |
|
+0.41% | +36.53% |
| 01:08am | Gilead signs generic licensing deals for experimental Ebola drug | RE |
| 12:47am | Gilead Signs Voluntary Licensing Deals to Expand Access to Investigational Ebola Drug | MT |
| Market Cap | 208B 189B 175B 158B 298B 19,575B 309B 2,104B 834B 10,505B 782B 766B 33,274B | P/E 2026 * |
-39.5x | P/E 2027 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise Value | 230B 209B 193B 174B 328B 21,551B 340B 2,317B 918B 11,565B 861B 843B 36,634B | EV / Sales 2026 * |
7.31x | EV / Sales 2027 * | 6.55x |
| Free-Float |
99.88% | Yield 2026 * |
1.96% | Yield 2027 * | 2.01% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GILD | Delayed | |
| GILD | Real-time | ||
| GILD * | End-of-day quote | ||
| GIS | Real-time | ||
| GIS | Delayed | ||
| GIS | Real-time | ||
| GIS | Delayed | ||
| GIS | Delayed | ||
| 0QYQ | Delayed | ||
| GILD | End-of-day quote | ||
| 1GILD | End-of-day quote | ||
| GILD | Delayed | ||
| GILD | End-of-day quote | ||
| GILDUS | End-of-day quote | ||
| GILDCL | End-of-day quote | ||
| GILD | Delayed | ||
| 0QYQ | Real-time | ||
| Real-time |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -0.30% | ||
| 1 week | +0.41% | ||
| Current month | -1.82% | ||
| 1 month | +6.49% | ||
| 3 months | +21.12% | ||
| 6 months | +29.33% | ||
| Current year | +36.53% |
| 1 week | 166.75 | 171.8 | |
| 1 month | 151.71 | 176.58 | |
| Current year | 116.88 | 176.58 | |
| 1 year | 116.88 | 176.58 | |
| 3 years | 62.07 | 176.58 | |
| 5 years | 57.16 | 176.58 | |
| 10 years | 56.56 | 176.58 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/2/26 A | Sell | Chief Executive Officer | -15,000 | 0.0012% | ||
| 10/15/26 A | Sell | Executive/Senior Manager | -3,000 | 0.0002% | ||
| 10/15/26 A | Sell | Chief Financial Officer | -3,000 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.30% | +0.41% | +34.04% | +123.32% | 208B | ||
| -0.82% | +5.74% | +39.64% | +143.26% | 1,286B | ||
| -1.12% | +2.29% | +44.21% | +89.89% | 688B | ||
| -0.16% | +1.11% | +26.76% | +114.06% | 521B | ||
| +1.14% | +4.87% | +43.06% | +71.97% | 386B | ||
| -2.23% | -1.55% | +55.47% | +42.54% | 364B | ||
| +1.27% | +2.01% | +30.01% | +62.35% | 302B | ||
| +0.37% | +0.75% | +3.71% | +39.09% | 287B | ||
| -0.72% | +0.41% | +37.29% | +69.33% | 252B | ||
| +2.44% | +5.86% | -8.29% | -57.68% | 181B | ||
| Average | +0.26% | +2.20% | +30.59% | +69.81% | 448B | |
| Weighted average by Cap. | -0.01% | +3.26% | +35.14% | +91.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 31.38B 28.51B 26.34B 23.79B 44.91B 2,947B 46.48B 317B 126B 1,581B 118B 115B 5,009B | 33.6B 30.53B 28.21B 25.48B 48.08B 3,155B 49.77B 339B 134B 1,693B 126B 123B 5,363B |
| Net income | -5.29B -4.81B -4.44B -4.01B -7.57B -497B -7.84B -53.42B -21.17B -267B -19.86B -19.44B -845B | 10.7B 9.72B 8.98B 8.11B 15.31B 1,004B 15.84B 108B 42.78B 539B 40.14B 39.29B 1,707B |
| Net Debt | 21.05B 19.12B 17.67B 15.96B 30.12B 1,976B 31.17B 212B 84.18B 1,061B 78.98B 77.3B 3,359B | 11.61B 10.55B 9.75B 8.8B 16.61B 1,090B 17.2B 117B 46.44B 585B 43.57B 42.65B 1,853B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/11/26 | $167.58 | -0.30% | 4,582,784 |
| 13/11/26 | $168.08 | +0.08% | 3,637,695 |
| 12/11/26 | $167.95 | -1.05% | 4,233,733 |
| 11/11/26 | $169.73 | -0.67% | 4,883,537 |
| 10/11/26 | $170.87 | +0.92% | 4,830,594 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions

















